Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

about

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

Item

http://www.wikidata.org/entity/Q55395981

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@en

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@nl

type

Item

label

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@en

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@nl

prefLabel

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@en

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@nl

P1476

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.

@en

P2093

Arun Kumar A Raajasekar

http://www.w3.org/2001/XMLSchema#string

B Mark Evers

http://www.w3.org/2001/XMLSchema#string

Heidi L Weiss

http://www.w3.org/2001/XMLSchema#string

Le Aundra Murray

http://www.w3.org/2001/XMLSchema#string

Lowell Anthony

http://www.w3.org/2001/XMLSchema#string

Susanne Arnold

http://www.w3.org/2001/XMLSchema#string

Zainab Farooqui

http://www.w3.org/2001/XMLSchema#string

Zin War Myint

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors

92-Gene molecular profiling in identification of cancer origin: a retrospective study in Chinese population and performance within different subgroups

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.

Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.

Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Metastatic carcinoid tumors: a clinical review.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

P304

3519247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/3519247

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Aman Chauhan

P577

2018-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29853889

http://www.w3.org/2001/XMLSchema#string

P932

5964580

http://www.w3.org/2001/XMLSchema#string